Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1474-760X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models ; volume:17 ; number:1 ; day:21 ; month:9 ; year:2016 ; pages:1-11 ; date:12.2016
Genome biology ; 17, Heft 1 (21.9.2016), 1-11, 12.2016
- Urheber
-
Geeleher, Paul
- Beteiligte Personen und Organisationen
-
Cox, Nancy J.
Huang, R. Stephanie
SpringerLink (Online service)
- DOI
-
10.1186/s13059-016-1050-9
- URN
-
urn:nbn:de:101:1-2018071920361988811073
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Geeleher, Paul
- Cox, Nancy J.
- Huang, R. Stephanie
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biomarker discovery
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle
Metagenomic biomarker discovery and explanation
Biomarker discovery an related topics, 2
Avoiding false discovery in biomarker research
Opportunities for pharmacoproteomics in biomarker discovery
Revisiting biomarker discovery by plasma proteomics
Advanced technologies, including new biomarker discovery
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
GPS driving: a digital biomarker for preclinical Alzheimer disease
Genome-wide epigenomic profiling for biomarker discovery
Biomarker discovery
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle
Metagenomic biomarker discovery and explanation
Biomarker discovery an related topics, 2
Avoiding false discovery in biomarker research
Opportunities for pharmacoproteomics in biomarker discovery
Revisiting biomarker discovery by plasma proteomics
Advanced technologies, including new biomarker discovery
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
GPS driving: a digital biomarker for preclinical Alzheimer disease
Genome-wide epigenomic profiling for biomarker discovery
Biomarker discovery
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle
Metagenomic biomarker discovery and explanation
Biomarker discovery an related topics, 2
Avoiding false discovery in biomarker research
Opportunities for pharmacoproteomics in biomarker discovery
Revisiting biomarker discovery by plasma proteomics
Advanced technologies, including new biomarker discovery
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
GPS driving: a digital biomarker for preclinical Alzheimer disease